[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chang Gung Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,45,71,92,120,148,181,209,235,261,286,307,337,359,384,409,431,463,491,511,536,569,588,607,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100260801","ocean-registry-obesity-and-clock-for-elegant-aging-registry-100260801",false,"NCT02674230","OCEAN Registry: Obesity and Clock for Elegant Aging Registry","OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫","OCEAN","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* Body mass index ≥ 24 kg\u002Fm2\n* For normal subjects, Body mass index \\\u003C 24 kg\u002Fm2\n\nExclusion Criteria:\n\n* No inform consent\n* Use of steroid medications\n* Severe systemic diseases or organ failure with estimated life expectancy of 6 months or less",true,"ALL","20 Years",{"count":22,"type":23},2000,"ESTIMATED","10 Years","OBSERVATIONAL","This study aims to study the relationships between obesity, circadian rhythm, and aging. The investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. The cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. Clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.",[28,29,30,31],"Obesity","Circadian Dysregulation","Aging","Cardiovascular Disease","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":4},"2011-07",{"date":40,"type":23},"2035-06",{"name":42,"class":43},"Chang Gung Memorial Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100641582","the-anorectal-function-and-qol-of-patients-receiving-transrectal-nose-via-rigid-tamis-platform-in-minimal-invasive-colon-surgery-100641582","NCT07653607","The Anorectal Function and QoL of Patients Receiving Transrectal NOSE Via Rigid TAMIS Platform in Minimal Invasive Colon Surgery","A Prospective, Multi-Center, Single-Arm, Open-Label Study to Analyze Anorectal Function and Quality of Life in Patients Undergoing Minimally Invasive Colectomy With Transrectal Natural Orifice Specimen Extraction (NOSE) Using a Rigid Transanal Minimally Invasive Surgery (TAMIS) Platform","Inclusion Criteria:\n\n1. Male or female, aged above 18 years, inclusive.\n2. Patients scheduled for an elective laparoscopic or robotic-assisted colectomy above sigmoid colon.\n3. Deemed a suitable candidate for the Transrectal NOSE procedure by the treating surgical team, based on tumor size (generally, largest diameter \\\u003C 4 cm), tumor T stage(1-3), location, and patient anatomy.\n4. American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Able to understand the purpose, procedures, potential risks, and benefits of the study and willing to provide written informed consent, as approved by the Institutional Review Board (IRB).\n6. Willing and able to comply with all scheduled follow-up visits and assessment procedures outlined in the protocol.\n\nExclusion Criteria:\n\n1. Pre-existing moderate-to-severe fecal incontinence, defined as a Wexner incontinence score \\> 8.\n2. History of any prior anal surgery (e.g., sphincteroplasty, artificial sphincter implantation, fistulotomy), major pelvic surgery (e.g., hysterectomy, radical prostatectomy), or pelvic radiation therapy.\n3. Confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis).\n4. The planned surgical procedure requires a protective stoma.\n5. Uncorrectable coagulopathy identified on preoperative assessment.\n6. Known neurological condition affecting bowel control (e.g., spinal cord injury, multiple sclerosis, significant post-stroke deficits).\n7. Cognitive impairment, severe psychiatric illness, or other condition that would interfere with reliable completion of questionnaires or compliance with the protocol.\n8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period.\n9. Concurrent participation in another interventional clinical trial that could potentially interfere with the study outcomes.\n10. Any other condition which, in the professional opinion of the investigator, makes the subject unsuitable for participation in this study.","18 Years",{"count":54,"type":23},57,"INTERVENTIONAL",[57],"NA","The primary objective of this study is to prospectively determine and precisely estimate the incidence of Internal Anal Sphincter (IAS) Injury at 12 months following colectomy with Transrectal NOSE.",[60,61],"Minimal Invasive Surgery","Colon Surgery","NOT_YET_RECRUITING","2026-06-15",{"date":65,"type":36},"2026-06-17",{"date":67,"type":23},"2026-06-01",{"date":69,"type":23},"2029-07-31",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100642700","fnirs-for-monitoring-cortical-activity-in-stroke-recovery-100642700","NCT07623512","fNIRS for Monitoring Cortical Activity in Stroke Recovery","Functional Near-infrared Spectroscopy (fNIRS) is an Ideal Tool to Monitor Cortical Brain Activity and Understand the Mechanism Underlying Recovery Following Stroke","Stroke participants\n\nInclusion Criteria:\n\n* unilateral stroke onset ≥ 3 months\n* Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score between 18 to 56 - modified Ashworth scale ≤ 3 in proximal joints and modified Ashworth scale ≤ 2 in distal joints\n* able to follow 2-step instructions\n* without excessive spasticity in any of the UE joints.\n\nExclusion Criteria:\n\n* orthopedic conditions affecting the arm\u002Fhand or other neurological conditions\n* severe pain that prevents movement in the affected arm and hand\n* implanted cardiac pacemakers and cardioverter-defibrillators\n* osteoporosis, fracture, or severe ataxia\n* unstable medical status\n* participating in other rehabilitation or drug studies simultaneously\n* receiving Botulinum toxin injections within 3 months\n\nHealthy participants\n\n* have no neurological conditions\n* have no musculoskeletal disorders affecting the UE",{"count":79,"type":23},108,[57],"This clinical trial aims to investigate the mechanisms of brain reorganization underlying motor recovery following end-effector (EE) and exoskeleton (Exo) robot-assisted hand training in individuals with stroke. Using functional near-infrared spectroscopy (fNIRS), the study will (1) investigate brain activation patterns during EE and Exo robot-assisted hand movements in healthy adults and individuals with stroke and (2) examine longitudinal changes in brain activation and motor recovery over a 6-week intervention.\n\nFor Part 1, a cross-sectional observational study will be conducted to examine brain activation using fNIRS while participants perform EE and Exo robot-assisted movements. Healthy adults and individuals with stroke will each perform one session of each type of robot-assisted movement.\n\nFor Part 2, an evaluator-blinded randomized controlled design will be used. Participants will be stratified based on the level of motor impairment and the side of the brain lesion and then randomly assigned to either the EE or Exo robot-assisted training group. Both groups will receive training 3 times per week, with each session lasting 60 minutes, for a total of 6 weeks. Each session will include 40 minutes of robot-assisted therapy and 20 minutes of functional training.\n\nOutcome assessments will be conducted at four time points: prior to the intervention (baseline), mid-intervention (during weeks 3-4 of the intervention), immediately after the intervention, and at the 3-month post-trial follow-up. These assessments will be used to evaluate motor recovery and longitudinal changes in brain function.",[83],"Stroke","2026-06-14",{"date":86,"type":36},"2026-06-16",{"date":88,"type":36},"2025-11-28",{"date":90,"type":23},"2028-12-31",{"name":42,"class":43},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":18,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":55,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100642761","the-effectiveness-of-a-digital-career-focused-mobile-application-on-nursing-students-career-planning-and-career-trajectories--100642761","NCT07628673","The Effectiveness of a Digital Career-Focused Mobile Application on Nursing Students' Career Planning and Career Trajectories .","NurseBridge","Inclusion Criteria:\n\n* Currently in their final year of nursing studies (including five-year vocational colleges, four-year technical colleges, and universities).\n* Possess a mobile phone with internet access.\n* Be of sound mind and able to understand and answer researchers' questions.\n* Be able to understand spoken or written Chinese.\n* Be willing to participate in this study and sign a participant consent form.\n\nExclusion Criteria:\n\n* Nursing two-year technical college students.\n* Those with full-time or part-time clinical nursing work experience.\n* Those unwilling to participate in this study.",{"count":100,"type":23},148,[57],"Methods: This three-year experimental study is divided into two phases. In the first phase, a mixed-methods approach will be used. During this phase, a mobile application based on the Career Planning Model will be developed, followed by a pilot study to perform user testing and evaluate usability. The second phase will employ a prospective, double-blind randomized controlled trial (RCT) design, utilizing the nursing career planning application developed in the first phase for a six-month intervention study. A total of 108 senior-year nursing students (54 in the intervention group and 54 in the control group) will be invited to participate inthe study.",[104],"This Study Will Develop Nurse Bridge and Test Its Six-month Effects on Nursing Students' Career Outcomes Using a Two-phase Randomized Controlled Trial",[106,107,108,109,110,111,112],"career planning behaviors","career resilience","professional identity","nursing career persistence intentions","career self-efficacy","persistence intentions","nursing students' study","2026-06-12",{"date":63,"type":36},{"date":116,"type":23},"2026-07-01",{"date":118,"type":23},"2029-10-30",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":128,"enrollmentInfo":129,"targetDuration":131,"studyType":25,"phases":4,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100642660","glucose-homeostasis-and-shared-genetic-factors-in-colorectal-cancer-100642660","NCT07648589","Glucose Homeostasis and Shared Genetic Factors in Colorectal Cancer","Genetic and Molecular Insights Into Glucose Homeostasis and Colorectal Cancer: Exploring Pleiotropic Genes and Mechanistic Roles in Colorectal Cancer Patients","BRIDGE-CRCDM","Inclusion Criteria:\n\n* Age 20 to 85 years\n* Histologically confirmed colorectal cancer\n* Newly diagnosed colorectal cancer at the time of enrollment\n* No prior diagnosis of diabetes mellitus\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 20 years or older than 85 years\n* Pre-existing diagnosis of diabetes mellitus\n* Severe obesity (body mass index ≥35 kg\u002Fm²)\n* Pregnancy\n* Inability or unwillingness to provide informed consent","85 Years",{"count":130,"type":23},200,"2 Years","Colorectal cancer (CRC) and diabetes mellitus are two common diseases that frequently occur together and may share underlying genetic, metabolic, and immune-related mechanisms. Previous studies have shown that diabetes is associated with an increased risk of colorectal cancer and poorer clinical outcomes, while colorectal cancer itself may also influence glucose metabolism.\n\nThis prospective observational study aims to investigate the relationships among glucose homeostasis, shared genetic factors, inflammatory responses, immune cell profiles, and colorectal cancer outcomes. Participants with colorectal cancer and non-colorectal cancer controls will undergo serial assessments of glucose-related biomarkers, inflammatory markers, immune cell populations, and genetic analyses over time.\n\nThe study will focus on identifying shared genetic variants that may contribute to both colorectal cancer and diabetes-related traits, as well as exploring biological pathways involving inflammation, immune regulation, and metabolism. Blood samples and available colorectal tissue specimens will be analyzed to evaluate gene expression, immune cell distribution, and molecular changes associated with disease progression.\n\nThe results of this study may improve understanding of the biological links between colorectal cancer and diabetes, facilitate the development of personalized risk assessment strategies, and identify potential biomarkers and therapeutic targets for patients with colorectal cancer.",[134,135,136],"Colorectal Cancer","Diabetes Mellitus","Glucose Homeostasis",[134,135,136,138,139,140,141],"Hyperglycemia","SMAD7","Pleiotropic Genes","Cancer Genomics","2026-06-11",{"date":63,"type":36},{"date":67,"type":23},{"date":146,"type":23},"2029-05-30",{"name":42,"class":43},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":19,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":55,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":44},"100597125","repetitive-transcranial-magnetic-stimulation-combined-with-bimanual-therapy-for-upper-limb-stroke-rehabilitation-100597125","NCT07054424","Repetitive Transcranial Magnetic Stimulation Combined With Bimanual Therapy for Upper Limb Stroke Rehabilitation","Development of Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Machine-assisted Bimanual Therapy (BT) in Upper Limb Rehabilitation","Inclusion Criteria:\n\n1. Age 40-80 years;\n2. First-onset stroke patients;\n3. Patients diagnosed with cerebral infarction or hemorrhage through CT or MRI;\n4. Signed informed consent form by the patient and their family;\n5. Stable physiological parameters;\n6. Stroke occurred within the last 12 months;\n7. Patients with unilateral hand function impairment caused by the stroke;\n8. Upper limb muscle tone (Modified Ashworth Scale, MAS) less than 3 points;\n9. Able to follow two-step commands.\n\nExclusion Criteria:\n\n1. A history of epilepsy or family history of epilepsy;\n2. Presence of suicidal tendencies;\n3. Currently using medications that lower the seizure threshold;\n4. Pregnant or planning to become pregnant;\n5. Co-existing neurological diseases (such as multiple sclerosis, other neurodegenerative diseases, meningitis, brain abscess, or meningioma);\n6. Subjects with uncontrollable migraines caused by elevated intracranial pressure;\n7. Subjects taking antidepressants who cannot discontinue the medication;\n8. Subjects with sleep disorders during rTMS treatment;\n9. Subjects with cerebellar stroke or brainstem stroke;\n10. Cerebral ischemic disorders resulting from traumatic brain injury;\n11. Transient ischemic attacks (TIAs);\n12. History of bleeding tendency and other conditions affecting upper limb function, such as myasthenia gravis, systemic immune neuropathy, severe epilepsy, endocrine system disorders, wearers of external or internal cardiac pacemakers, individuals with metallic implants or orthopedic devices;\n13. Co-existing severe heart, liver, kidney dysfunction, or other serious physical illnesses;\n14. Subjects with impaired consciousness who cannot cooperate with examinations or treatments, such as those with mental disorders, or those with intellectual or cognitive impairments, severe dementia;\n15. Presence of implanted electronic devices in the body;\n16. Co-existing severe liver, kidney, or hematological disorders;\n17. Special vulnerable populations;\n18. Skin disease (e.g., pressure ulcers, trauma, cellulitis, etc.).","40 Years","80 Years",{"count":158,"type":23},54,[57],"The goal of this clinical trial is to evaluate whether combining repetitive transcranial magnetic stimulation (rTMS) with machine-assisted bimanual therapy (BT) can improve upper limb function in stroke patients. The participants will be individuals aged 40-80 years who have experienced a first-time ischemic or hemorrhagic stroke. The main questions it aims to answer are:\n\n* Does the combined therapy enhance motor recovery compared to traditional rehabilitation methods?\n* Are changes in brain activity associated with improvements in upper limb function?\n\nParticipants will be randomly assigned to different groups and will:\n\n* Receive rTMS stimulation on specific areas of the brain to modulate neural activity,\n* Perform machine-assisted bimanual exercises to promote motor skills, and\n* Undergo assessments before, immediately after, and during follow-up periods to measure functional improvements.",[162,163,164,165],"Post-stroke Upper Limb Hemiparesis","Repetitive Transcranial Magnetic Stimulation (rTMS)","Bimanual Therapy","Neuromodulation",[83,167,168,169,170,171,172,173],"neurorehabilitation","rTMS","bimanual therapy","neuromodulation","upper limb function","theta burst stimulation","brain plasticity","2026-06-10",{"date":142,"type":36},{"date":177,"type":36},"2025-06-05",{"date":179,"type":23},"2027-07-31",{"name":42,"class":43},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100643204","ctdna-monitoring-after-pancreatic-cancer-surgery-k-4care-lite-study-100643204","NCT07597252","ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)","A Prospective Observational Study of Circulating Tumor DNA Dynamic Monitoring Using K-4CARE Lite Platform After Curative Resection of Pancreatic Cancer","K4CARE-PDAC","Inclusion Criteria:\n\n* Age 20 years or older\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), including its histological subtypes\n* Has undergone curative-intent resection (R0 or R1, defined as margin \\\u003C1 mm), via pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy\n* Post-operative pathologic stage at least pT1, with N0 or N1 or higher\n* Computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks before enrollment confirming no evidence of residual tumor and no distant metastasis\n* Intent to receive adjuvant chemotherapy\n* Sufficient surgical FFPE tumor tissue available for genomic sequencing\n* Able to understand and provide signed informed consent\n* Patients with or without prior neoadjuvant chemotherapy are both eligible\n\nExclusion Criteria:\n\n* Post-operative pathologic stage IV (distant metastasis), or R2 resection\n* Concurrent active primary malignancy (except cured non-melanoma skin cancer or carcinoma in situ within the past 5 years)\n* Severe post-operative complications precluding initiation of adjuvant chemotherapy within 12 weeks\n* Receipt of post-operative radiation therapy\n* Known hematologic disease or myeloproliferative disorder that may significantly affect ctDNA assay accuracy\n* Pregnant or breastfeeding women\n* Unable to comply with the protocol-specified blood draw schedule",{"count":190,"type":23},30,"Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years. Current post-operative surveillance relies on computed tomography (CT) imaging and the serum tumor marker CA 19-9, but both have limited sensitivity for detecting microscopic residual disease.\n\nThis single-center, prospective observational study evaluates the use of the K-4CARE Lite platform-a tumor-informed plus tumor-agnostic circulating tumor DNA (ctDNA) assay with a limit of detection of 0.005%-for dynamic monitoring of minimal residual disease (MRD) in patients with resected PDAC.\n\nThirty adult patients who have undergone R0 or R1 (margin \\\u003C1 mm) resection at Linkou Chang Gung Memorial Hospital will be enrolled over 24 months. Each participant will provide one baseline tumor tissue sample (formalin-fixed paraffin-embedded) and three serial blood samples at three pre-specified study timepoints: Timepoint 1 (Week 4 to Week 10 after surgery, before adjuvant chemotherapy); Timepoint 2 (12 weeks after Timepoint 1, approximately 3 months into adjuvant chemotherapy); and Timepoint 3 (at completion of adjuvant chemotherapy, approximately Month 6 after surgery). A fourth long-term follow-up phase (Timepoint 4) collects results from patient-funded ctDNA testing performed as part of routine care.\n\nThe primary outcome is the cumulative MRD detection rate across the three pre-specified post-surgical timepoints (Timepoint 1, Timepoint 2, and Timepoint 3). Secondary outcomes include the association between ctDNA status and disease-free survival (DFS) and overall survival (OS), molecular clearance rate at Timepoint 3, lead time of molecular relapse over imaging, and platform performance. ctDNA results are reported back to the treating physician for reference but do not mandate treatment changes-all clinical decisions remain at the physician's discretion per standard guidelines.\n\nThis study aims to generate the prospective evidence base needed to design future ctDNA-guided interventional trials in pancreatic cancer.",[193,194],"Pancreatic Ductal Adenocarcinoma (PDAC)","NGS Monitor MRD",[196,197,198,199,200,201,202],"pancreatic cancer","circulating tumor DNA","minimal residual disease","tumor-informed sequencing","adjuvant chemotherapy","liquid biopsy","K-4CARE Lite","2026-06-07",{"date":174,"type":36},{"date":67,"type":23},{"date":207,"type":23},"2029-04-30",{"name":42,"class":43},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":55,"phases":218,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":44},"100620976","phase-2-fecal-microbiota-transplantation-for-steroid-refractory-acute-gi-gvhd-100620976","NCT07364617","Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD","Fecal Microbiota Transplantation for the Treatment of Steroid Refractory Acute Gastrointestinal Graft-Versus-Host Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Stage II to IV steroid refractory acute GI-GvHD in allo-HSCT recipients\n\n   1. Stage II to IV acute GI-GVHD subjects, having \\>1000 mL stool per day, diarrhea \\> 5 times\u002Fday, or abdominal cramping, bleeding or ileus, AND\n   2. Resistant to a first-line therapy with corticosteroids (CS)\n\n   \u003C!-- -->\n\n   1. Lack of improvement after 5 days of treatment with CS at 2 mg\u002Fkg\u002Fd methylprednisolone or other CS with equivalent dose,\n   2. Progression after 3 days of treatment with CS at 2 mg\u002Fkg\u002Fd methylprednisolone or other CS with equivalent dose.\n2. Age ≥ 18 years old.\n3. Allo-HSCT with any type of donor, stem cell source, GvHD prophylaxis or conditioning regimen.\n4. Allow vancomycin-resistant enterococcus (VRE) colonization and asymptomatic cytomegalovirus (CMV) viremia, which is defined as a detectable CMV viral load in plasma but without tissue-invasive disease.\n5. Patients able to have a minimum of 12 hours discontinuation of systemic antibiotics in order to perform the allogeneic FMT (antiviral and antifungal agents are allowed)\n6. Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship. Subject must understand and voluntarily sign an informed consent form prior to any study-related assessments\u002Fprocedures being conducted.\n\nExclusion Criteria:\n\n1. Absolute neutrophil count \\\u003C 500 cells\u002FuL.\n2. Absolute platelet count \\\u003C 30000 \u002FuL which is not correctable by transfusion\n3. Hemodynamically unstable status with the following conditions: systolic blood pressure \\\u003C 90 mm Hg, pulse oximeter oxygen saturation (SpO2) \\\u003C 90%, PaO2 \\\u003C 60 mm Hg, or respiratory rate \\> 22\u002Fminute.\n4. Uncontrolled and active infection from bacteria, virus, or fungus as determined by the investigators.",{"count":217,"type":23},35,[219],"PHASE2","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD), particularly acute gastrointestinal GvHD (GI-GvHD). GvHD occurs when donor T cells recognize the recipient's tissue as foreign and mount an immune attack against it. Acute GI-GvHD is a common complication following allo-HSCT and a significant cause of mortality. If the initial steroid treatment for acute GvHD fails, mortality rates can reach as high as 81%.\n\nRecent studies have shown a strong association between reduced gut microbiota diversity and high mortality in patients with acute GI-GvHD, highlighting the critical role of the gut microbiome in regulating immune responses and maintaining intestinal homeostasis. Consequently, fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy aimed at restoring a healthy gut microbiome and improving clinical outcomes in patients with acute GI-GvHD.\n\nThis study aims to evaluate the efficacy and safety of FMT in patients with steroid-refractory or steroid-resistant acute GI-GvHD. The findings of this research will contribute to establishing FMT as a potential and effective treatment option for managing severe acute GI-GvHD, thereby improving patient outcomes and reducing transplant-related mortality.",[222],"Graft vs Host Disease",[224,225,226],"Acute Gastrointestinal Graft-versus-Host Disease","fecal microbiota transplantation","steroid-refractory","2026-05-21",{"date":229,"type":36},"2026-05-22",{"date":231,"type":36},"2026-04-29",{"date":233,"type":23},"2028-02-28",{"name":42,"class":43},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":55,"phases":244,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":44},"100509732","comparing-mindfulness-based-breath-training-and-heart-rate-variability-biofeedback-for-shoulder-surgery-patients-in-the-postoperative-pain-100509732","NCT05917262","Comparing Mindfulness-based Breath Training and Heart Rate Variability Biofeedback for Shoulder Surgery Patients in the Postoperative Pain.","Comparing Preoperative Mindfulness-based Breath Training and Heart Rate Variability Biofeedback for Shoulder Surgery Patients in the Postoperative Pain, Shoulder Function, Emotion, Sleep, Quality of Life, Cognitive Function, and Electroencephalography","Inclusion Criteria:\n\nshoulder pain patients with\n\n* (1) pain ≥3months and ≥3 days per week\n* (2) pain intensity ≥ 40 (VAS scale from 0 no pain to 100 very painful)\n* (3) the surgical indication would be based on orthopedics opinions\n\nExclusion Criteria:\n\n* history of shoulder surgery in the prior 3 years\n* osteoporotic vertebral fractures or rheumatologic diseases\n* chronic widespread pain syndromes (fibromyalgia or chronic fatigue syndrome)\n* neurological disease (i.e., stroke, parkinson's disease, etc..)\n* psychiatric disease (i.e., dementia, depression, schizophrenia, etc)\n* cancer\n* patients who practiced yoga, meditation, chi-qong, mindfulness, or deep breathing exercises more than three times per week",{"count":243,"type":23},120,[57],"Although shoulder surgeries can effectively relieve pain intensity and restore shoulder function, some patients reported persistent post-operative pain at the 6-month post-surgery follow-up visit. This randomized study aims to determine the effectiveness of three different types of bio-psychosocial support to pre-operative shoulder surgery patients. This study will examine the differential effects of brief mindfulness-based breathing, heart rate variability biofeedback (HRV-BF), and cognitive behavioral pain psychoeducation for pre-operative patients.",[247,248],"Pain, Postoperative","Shoulder Pain",[250,251,252,253,254],"Shoulder pain","Postoperative pain","mindfulness","HRV","biofeedback",{"date":229,"type":36},{"date":257,"type":36},"2023-11-13",{"date":259,"type":23},"2026-12-31",{"name":42,"class":43},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":55,"phases":271,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":285},"100533721","phase-1-dose-escalation-and-dose-expansion-study-of-gas-in-subjects-with-metastatic-pancreatic-adenocarcinoma-100533721","NCT06229496","Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma","A Phase 1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of S-1 in Combination With Nab-paclitaxel and Gemcitabine (GAS) in Subjects With Metastatic Pancreatic Adenocarcinoma","GAS","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed pancreatic adenocarcinoma (poorly differentiated carcinoma is allowed in the absence of neuroendocrine features or squamous differentiation)\n2. Treatment-naï ve stage IV disease (measurable disease is required). Prior adjuvant chemotherapy or radiochemotherapy is allowed, if completed ≥ 6 months before enrollment.\n3. Measurable disease defined as at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI\n4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-1\n5. Life expectancy \\> 6 months in the opinion of his\u002Fher treating physician.\n6. At least 18 years of age\n7. Ability to understand the nature of this study protocol, comply with study and\u002For follow-up procedures, and sign the IRB-approved written informed consent\n8. Fertile female and male patients with child-bearing potential agree to use adequate contraceptive measures prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n9. Adequate bone marrow function:\n\n   Absolute neutrophil count (ANC) ≥ 1500\u002FuL Platelet count ≥ 100,000\u002FuL Hemoglobin ≥ 9.0 g\u002FdL\n10. Adequate hepatic function:\n\n    Total bilirubin ≤ 1.5 X ULN (≤3.5 mg\u002FdL if with adequate biliary tract drainage\u002Fstent placement) AST ≤ 3.0 X ULN (≤5.0X ULN if liver metastases are present) ALT ≤ 3.0 X ULN (≤5.0X ULN if liver metastases are present)\n11. Adequate renal function (defined as serum creatinine ≤ 1.5 X ULN or creatinine clearance rate (CCr) ≥ 50 mL\u002Fmin (calculated by Cockroft-Gault formula; male: \\[(140 - age in years) × weight in kg)\\]\u002F\\[72 × serum creatinine(mg\u002FdL)\\];female=male x 0.85 )\n12. Able to take the oral study medication (S-1)\n13. No clinically significant abnormal ECG findings within 28 days (4 weeks) prior to enrollment\n\nExclusion Criteria:\n\n1. Have known endocrine pancreatic tumors or ampullary cancer\n2. Have received first line treatment for metastatic pancreatic cancer\n3. Have a serious concomitant active infection or other major comorbidities that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol (e.g., stroke, uncontrolled arrhythmia, heart failure, or active autoimmune disease)\n4. Have HIV history or hepatitis B and C infection, except for prescribing anti-hepatitis B medications for hepatitis B carrier and undetectable HCV RNA level for hepatitis C prior to enrollment.\n5. Have known central nervous system (CNS) malignancy or metastasis (screening is not required)\n6. Have concurrent hematologic malignancies, acute or chronic leukemia\n7. Have known additional malignancy that is progressing or required active treatments within the past 6 months, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast or cervical cancer)\n8. Women with a positive pregnancy test or who are breastfeeding\n9. Have participated within the last 30 days in a clinical trial involving an investigational product\n10. Unable to swallow capsules or has diseases significantly affecting gastrointestinal function or resection of the stomach or small bowel, malabsorption syndrome, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.\n11. Current peripheral sensory neuropathy ≥ Grade 2\n12. Any social condition or diseases judged ineligible by physician for participation in the study due to safety concern",{"count":270,"type":23},70,[272],"PHASE1","A Phase 1b, open-label, multicenter, dose escalation and dose expansion study of S-1 in combination with nab-paclitaxel and gemcitabine (GAS) in subjects with metastatic pancreatic adenocarcinoma. This study is a dose escalation and dose expansion study with the objective to establish the MTD and\u002For RP2D and\u002For DLT of nab-paclitaxel and gemcitabine in combination with a body surface area(BSA)-based dose of S-1 in subject with metastatic pancreatic adenocarcinoma.",[275],"Metastatic Pancreatic Adenocarcinoma",[277,278,267],"Dose escalation","Pancreatic adenocarcinoma","2026-05-19",{"date":229,"type":36},{"date":282,"type":36},"2023-08-01",{"date":90,"type":23},{"name":42,"class":43},3,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":55,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100637830","fecal-microbiota-transplantation-in-parkinsons-disease-100637830","NCT07597421","Fecal Microbiota Transplantation in Parkinson's Disease.","Fecal Microbiota Transplantation for the Treatment of Patients With Parkinson's Disease.","FMT","Inclusion Criteria:\n\n1. Clinical diagnosis of idiopathic PD according to UK brain bank criteria.\n2. PD disease duration ≧5 years to avoid the possible misdiagnosis of atypical parkinsonism.\n3. Hoehn-Yahr stage 1-4\n4. Using levodopa in a currently fixed dose.\n5. Presence of motor complications (motor fluctuation or dyskinesia).\n6. Written informed consent.\n7. Age above 18.\n\nExclusion Criteria:\n\n1. Hoehn-Yahr stage 5. (wheelchair ridden or bedridden due to PD)\n2. Dementia (MMSE\\\u003C24), history of encephalitis, or brain organic lesions, including congenital or acquired structural abnormalities (which were detected through brain computed tomography scan or Magnetic Resonance Imaging) may affect neurological function, leading to various neurological deficits and mpairing the cognitive function.\n3. Current use of probiotics or in the past 3 months.\n4. For women with childbearing potential. (Female participants are suggested to prevent pregnancy during this trial and undergo a pregnancy test before enrollment.)\n5. Current need of antibiotics or use in the previous 3 months.\n6. End stage renal disease caused uremic encephalopathy or liver cirrhosis caused hepatic encephalopathy\n7. Immunocompromised state.",{"count":295,"type":23},58,[57],"Fecal microbiota transplantation (FMT) is an effective and safe treatment for Clostridioides difficile infection (CDI). Though CDI is the only indication for FMT, more and more preliminary data on FMT in neurological disorders are reported due to gut-brain axis. This study is a pilot study to apply FMT on patients with Parkinson's disease (PD). The effect of FMT on motor and non-motor symptoms in PD will be also evaluated.",[299],"Parkinson's Disease","2026-05-13",{"date":279,"type":36},{"date":303,"type":23},"2026-09-01",{"date":305,"type":23},"2029-04-07",{"name":42,"class":43},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":314,"targetDuration":316,"studyType":25,"phases":4,"briefSummary":317,"conditions":318,"keywords":323,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":44},"100639089","taiwan-ed-airway-quality-surveillance-registry-tear-100639089","NCT07574450","Taiwan ED Airway Quality Surveillance Registry (TEAR)","The Taiwan ED Airway Quality Surveillance Registry (TEAR): A Prospective Multicenter Observational Study","Inclusion Criteria:\n\n* Undergoing tracheal intubation in the emergency department during the study period\n\nExclusion Criteria:\n\n* Prehospital intubation; intubation performed solely for elective anesthesia\u002Fprocedural sedation outside emergency indications",{"count":315,"type":23},1200,"1 Month","This prospective, multicenter observational registry systematically captures all emergency department tracheal intubations across participating hospitals in Taiwan. The registry focuses on process quality indicators, including first-pass success, and patient-safety outcomes, including hypoxemia, hypotension, and peri-intubation cardiac arrest within 30 minutes of intubation. Routinely generated laboratory and physiologic variables are also collected to improve risk stratification and identify predictors of major adverse events. The study is non-interventional and does not alter clinical care.",[319,320,321,322],"Airway Management","Tracheal Intubation","Emergency Department","Peri-intubation Adverse Events",[324,325,326,327,328],"first-pass success","hypoxemia","hypotension","cardiac arrest","registry","2026-05-05",{"date":331,"type":36},"2026-05-08",{"date":333,"type":23},"2026-08",{"date":335,"type":23},"2029-12",{"name":42,"class":43},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":19,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":55,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":358,"locationsCount":44},"100640850","explore-the-impacts-of-theta-burst-stimulation-over-the-right-inferior-frontal-gyrus-in-autism-spectrum-disorder-combination-of-clinical-symptoms-neuropsychological-function-and-mri-100640850","NCT07579494","Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI","Inclusion Criteria:\n\n* Participants aged 8 to 30 years with a clinical diagnosis of Autism Spectrum Disorder (ASD), confirmed by the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition).\n* DSM-5 severity level of ASD: level 1 or level 2\n* Participants who have been on a stable treatment regimen prior to the study, or those for whom conventional treatments have been assessed as ineffective by a physician, or those who decline conventional treatment.\n* A score of ≥ 15 on the University of California Brief Assessment of Capacity to Consent (UBACC) and demonstrated understanding of study aims and risks via the teach-back method.\n\nExclusion Criteria:\n\n* Previous or current severe neurological disorders, especially epilepsy, visual or auditory impairments\n* Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension\n* Previous or current severe brain injury\n* Implementation of metal materials such as a pacemaker or medication pump\n* Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse\n* Pregnancy\n* Presence of significant brain abnormalities, such as intracranial space-occupying lesions\n* Previous brain surgery or central nerve system infection\n* Concurrent use of medications which increased the risk of seizure attack\n* Participate in another clinical trial within one month\n* With damaged skin at the stimulated region\n* With multiple sclerosis\n* With large ischemic scars\n* Have experienced sleep disorders during brain stimulation\n* Severe alcoholism\n* Concurrent use of antiepileptic drugs\n* Uncontrollable migraines due to increased intracranial pressure\n* Unsuitable for MRI (e.g. those with claustrophobia)\n* Unsuitable for EEG\n* DSM-5 severity level of ASD: level 3\n* Current major depressive disorder\n* Suicidal ideation within one year\n* Currently taking tricyclic antidepressants (TCAs), analgesics, or any medications known to lower the seizure threshold.\n\nWithdrawal Criteria:\n\n* Seizure attack during the study period\n* Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)\n* Extreme agitation or irritability during the study period\n* Participants request\n* Clinical symptoms worsened obviously during study period\n* Start to use antiepileptic drugs during study period\n* Suicidal ideation or self-harm behaviors during study period\n* Changes in the frequency or dosage of concurrent treatments during the study period.","8 Years","30 Years",{"count":346,"type":23},60,[57],"Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.",[350,351,352],"Autism Spectrum Disorder","Theta Burst Stimulation","Right Inferior Frontal Gyrus",{"date":354,"type":36},"2026-05-12",{"date":329,"type":36},{"date":357,"type":23},"2030-12-31",{"name":42,"class":43},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":128,"enrollmentInfo":366,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":382,"locationsCount":383},"100636689","impact-of-force-control-of-hip-abductor-muscles-in-healthy-adults-and-individuals-with-parkinsons-disease-100636689","NCT07568951","Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease","Impact of Force Control of Hip Abductor Muscles on Postural Control in Middle-aged and Older Adults and Individuals With Parkinson's Disease","Healthy people\n\nInclusion Criteria:\n\n* 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)\n* generally in good health\n* able to walk 10 m independently\n* able to follow all instructions\n\nExclusion Criteria:\n\n* neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study\n* any pain over the lower extremities\n* uncontrolled cardiovascular diseases\n* unable to provide informed consent.\n\nPD\n\nInclusion Criteria:\n\n* clinical diagnosis of idiopathic PD\n* Hoehn and Yahr stages 1 to 3\n* stable anti-PD medications\n* able to walk 10 m independently\n* able to follow all instructions\n\nExclusion Criteria:\n\n* psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study\n* neurological conditions other than PD\n* any pain over the lower extremities\n* uncontrolled cardiovascular diseases\n* unable to provide informed consent.",{"count":367,"type":23},210,"Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. While previous studies have mainly focused on sagittal plane balance, the contribution of hip abductor muscles remains unclear, especially regarding their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD.",[30,370],"Parkinson's Disease (PD)",[372,373,374,375,376,377],"Old","Parkinson's disease","muscle force","force steadiness","balance","gait performance","2026-05-04",{"date":331,"type":36},{"date":282,"type":36},{"date":69,"type":23},{"name":42,"class":43},2,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":391,"targetDuration":131,"studyType":25,"phases":4,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":44},"100595786","metabolomic-and-immune-microbiome-profiling-for-unresectable-pancreatic-cancer-100595786","NCT07036978","Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer","Integrative Metabolomic and Immune-Microbiome Profiling for Personalised Treatment Stratification in Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Unresectable disease status determined by a multidisciplinary tumour board (either locally advanced disease encasing critical vessels or distant metastases present).\n2. Planned initiation of systemic therapy (first-line chemotherapy or chemo + experimental immunotherapy trial) as part of standard care - this ensures a uniform starting point for outcome measurement.\n3. Adequate organ function to undergo therapy (renal, hepatic, bone marrow parameters within acceptable range) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating patients well enough to participate and undergo required blood draws and sample collection.\n4. Ability to provide informed consent, with no severe comorbid conditions that would preclude study procedures (e.g. unable to provide stool sample or undergo blood draws).\n\nExclusion Criteria:\n\n1. Prior systemic therapy for metastatic PDAC.\n2. Current use of long-term antibiotics or probiotics that could significantly alter the gut microbiome unless they are willing to pause these interventions (to avoid confounding in microbiome analysis).\n3. Co-existing active malignancy that could confound metabolomic or immune readouts, unless it is a low-grade, early cancer in remission.",{"count":392,"type":23},140,"Brief Summary\n\nThe goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are:\n\n* What serum metabolomic profiles predict treatment response and patient survival?\n* How do immune response markers and gut microbiome composition correlate with therapeutic outcomes?\n* Can a combined multi-omic stratification algorithm enhance personalised therapy planning?\n\nParticipants, who have been diagnosed with unresectable locally advanced or metastatic PDAC and are undergoing systemic therapy and chemoradiotherapy, will:\n\n* Provide serum samples for comprehensive metabolomic profiling via high-performance liquid chromatography-mass spectrometry.\n* Undergo immune profiling through flow cytometry.\n* Provide stool samples for gut microbiome analysis using 16S rRNA sequencing.\n* Be followed longitudinally to correlate these multi-omic findings with clinical outcomes.\n\nResearchers anticipate that integrating these multi-omic analyses will facilitate personalised therapy approaches, potentially improving patient outcomes.",[193],[396,397,398,399,400],"Pancreatic ductal adenocarcinoma","Metabolomics","Microbiome","Immune profiling","Multi-omic integration","2026-04-13",{"date":403,"type":36},"2026-04-15",{"date":405,"type":23},"2026-05-01",{"date":407,"type":23},"2033-07-31",{"name":42,"class":43},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":416,"targetDuration":131,"studyType":25,"phases":4,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":44},"100580005","metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer-100580005","NCT06831669","Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer","Metabolomic Profiles as Predictors of Treatment Response and Toxicities in Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the rectum\n* Scheduled to receive total neoadjuvant therapy\n\nExclusion Criteria:\n\n* Previous pelvic radiation therapy\n* Inflammatory bowel disease",{"count":417,"type":23},250,"Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases. Total neoadjuvant therapy (TNT), which consists of chemotherapy and radiation therapy delivered before surgery, has become the standard of care for locally advanced rectal cancer. However, there is currently no reliable method for predicting the response to TNT or the occurrence of radiation proctitis, a common side effect of treatment.\n\nObjective: This study aims to evaluate the metabolomic profiles of individuals with locally advanced rectal cancer undergoing TNT and to identify a panel of metabolites that can predict treatment response and toxicities.\n\nMethods: A prospective cohort study will be conducted to enrol patients with locally advanced rectal cancer who are scheduled to receive TNT. Blood, urine, tissue, and faecal samples will be collected at baseline, during, and after chemoradiotherapy. Metabolomic profiling of the samples will be performed using liquid-chromatography mass spectrometry (LC-MS). Treatment response will be assessed based on clinical downstaging (defined as a decrease in tumour size and\u002For T and N stage after TNT) and pathological response, such as pathological complete response (pCR). Radiation proctitis will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. PCA and PLSDA will be used to identify metabolites that are associated with treatment response and radiation proctitis. Receiver operating characteristic (ROC) curves will be used to assess the predictive performance of the identified metabolites. Univariate and multivariate logistic regression will be used to build models to predict treatment response and radiation proctitis.",[420],"Rectal Neoplasm Malignant",[422,423,397,424],"Rectal cancer","Total neoadjuvant therapy","Radiation proctitis",{"date":403,"type":36},{"date":427,"type":36},"2024-01-05",{"date":429,"type":23},"2033-12-12",{"name":42,"class":43},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":156,"enrollmentInfo":439,"targetDuration":4,"studyType":55,"phases":441,"briefSummary":442,"conditions":443,"keywords":448,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":4},"100631119","the-acure-trial-acupuncture-for-colorectal-recovery-100631119","NCT07496528","The ACURE Trial: Acupuncture for Colorectal Recovery","Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection","ACURE","Inclusion Criteria:\n\n* Histologically confirmed colorectal cancer requiring scheduled curative-intent resection.\n* Age between 18 and 79 years, inclusive.\n* Ability to understand the study protocol and provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of major abdominal surgery within the past 4 weeks.\n* Receipt of chemotherapy or radiotherapy within the past 6 months.\n* History of organ transplantation with rejection episodes within the past 30 days.\n* Presence of active infection (e.g., tuberculosis, sepsis, peritonitis).\n* Positive for hepatitis B, hepatitis C, or HIV with an uncontrolled viral load.\n* Severe malnutrition, defined as a Nutritional Risk Screening (NRS 2002) score ≥ 3.\n* History of total colectomy or requirement for ileorectal anastomosis.\n* Requirement for multivisceral resection due to tumor invasion.\n* Scheduled for prophylactic stoma creation.\n* Moderate to severe cognitive impairment, epilepsy, or uncontrolled neurological disorders.\n* Active psychiatric illness (e.g., bipolar disorder, schizophrenia) that may interfere with study compliance.\n* Severe cardiopulmonary insufficiency (e.g., New York Heart Association \\[NYHA\\] class IV heart failure or requirement for long-term oxygen therapy).\n* Presence of open wounds, skin infections, or known allergies at or near the designated acupuncture sites.\n\nHistory of adverse reactions to acupuncture, including syncope (fainting) or needle phobia.\n\nParticipation in another clinical trial within the past 6 months.\n\nAnticipated inability to complete the study protocol due to physical, psychological, or logistical reasons.",{"count":440,"type":23},240,[57],"Purpose:\n\nThe goal of this clinical trial is to evaluate whether electroacupuncture (EA) can accelerate the recovery of bowel function in patients undergoing minimally invasive surgery for colorectal cancer.\n\nMain Questions to be Answered:\n\nDoes electroacupuncture reduce the time to the first bowel movement after surgery compared to standard care or a \"sham\" (placebo) treatment?\n\nCan electroacupuncture improve overall gastrointestinal tolerance and reduce postoperative discomfort?\n\nStudy Design:\n\nParticipants will be randomly assigned to one of three groups:\n\nElectroacupuncture Group: Receives active electrical stimulation at specific acupuncture points.\n\nSham Acupuncture Group: Receives superficial needling at non-treatment points with no electrical current to serve as a placebo.\n\nStandard Care Group: Receives standard hospital recovery protocols (ERAS) without acupuncture.\n\nAll treatments will consist of four 30-minute sessions: one before surgery and three on the days following the procedure. Researchers will compare the three groups to see if the electroacupuncture group experiences a faster return of digestive function.",[444,445,446,447],"Colorectal Neoplasms","Ileus Postoperative","Postoperative Complication","Gastrointestinal Motility",[449,450,451,452,453,454],"electroacupuncture","acupuncture therapy","colorectal cancer","enhanced recovery after surgery","minimally invasive surgery","postoperative ileus","2026-03-31",{"date":457,"type":36},"2026-04-06",{"date":459,"type":23},"2026-04-01",{"date":461,"type":23},"2029-05-31",{"name":42,"class":43},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":18,"sex":19,"minAge":469,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":55,"phases":472,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":44},"100632252","prediction-of-cognitive-test-performance-using-ai-based-analysis-of-narrative-speech-100632252","NCT07511270","Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech","Inclusion Criteria:\n\n1. Age 50 years or older\n2. Able to communicate verbally and understand study instructions\n3. Able to hear and speak clearly\n4. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe speech or hearing impairment\n2. History of major psychiatric disorders\n3. History of stroke, traumatic brain injury, Parkinson's disease, epilepsy, or other neurodegenerative diseases\n4. Current use of medications that may affect cognitive performance\n5. Unable to complete the study procedures due to severe attention deficits or agitation","50 Years",{"count":471,"type":23},150,[57],"This study aims to evaluate a new artificial intelligence (AI)-based method for measuring cognitive function using speech recordings. Participants will complete a short storytelling task in which they describe a story based on an image while their voice is recorded using a computer or mobile device.\n\nThe speech recordings will be analyzed using AI technology to identify patterns in speech that may be related to cognitive function. The system will then estimate scores that correspond to commonly used cognitive tests.\n\nTo evaluate the accuracy of this method, the AI-generated scores will be compared with results from standard cognitive assessments administered by trained researchers. These assessments may include tests commonly used to measure memory, attention, and other cognitive abilities.\n\nThe goal of this study is to determine whether speech analysis using AI can provide a convenient and efficient approach for cognitive assessment. If successful, this technology may help support early detection of cognitive decline and provide a practical tool for large-scale or remote cognitive screening.",[475,476,477],"Cognitive Function Assessment","Mild Cognitive Impairment","Subjective Cognitive Decline",[479,480,481,482,483,476],"Artificial Intelligence","Speech Biomarkers","Storytelling Task","Cognitive Screening","Voice Analysis","2026-03-30",{"date":457,"type":36},{"date":487,"type":36},"2025-12-01",{"date":489,"type":23},"2026-04-30",{"name":42,"class":43},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":19,"minAge":52,"maxAge":4,"enrollmentInfo":498,"targetDuration":500,"studyType":25,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100630604","metabolomic-pathways-and-traditional-chinese-medicine-body-constitution-in-cancer-related-fatigue-100630604","NCT07489833","Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue","The Exploration of the Relationship Between Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue in Patients With Colorectal Cancer","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Diagnosed with stage I to III CRC and scheduled for surgical treatment\n* Cognitively intact and able to communicate in either Mandarin or Taiwanese\n* Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients diagnosed with stage IV colorectal cancer\n* Patients with recurrent colorectal cancer or other concurrent cancers.",{"count":499,"type":23},80,"3 Months","The aim of this study is to integrate insights from metabolomics and TCMBC to identify biomarkers and physiological pathways associated with CRF.",[134],"2026-03-24",{"date":505,"type":36},"2026-03-27",{"date":507,"type":23},"2026-04-20",{"date":509,"type":23},"2029-02-28",{"name":42,"class":43},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":518,"targetDuration":520,"studyType":25,"phases":4,"briefSummary":521,"conditions":522,"keywords":526,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":44},"100631534","development-of-a-clinical-skills-teaching-video-database-in-occupational-therapy-100631534","NCT07501936","Development of a Clinical Skills Teaching Video Database in Occupational Therapy","Development of an Occupational Therapy Clinical Skills Teaching and Assessment Video Database","Inclusion Criteria:\n\n* Occupational therapists involved in clinical teaching activities\n* Occupational therapy interns or postgraduate trainees receiving clinical training\n* Adult patients (aged 20 years or older) or family members who receive occupational therapy services provided by participating therapists or trainees\n* Able and willing to provide informed consent for video or audio recording\n\nExclusion Criteria:\n\n* Individuals who are unwilling or unable to provide informed consent for video or audio recording\n* Individuals with significant cognitive impairment or communication difficulties that prevent informed consent\n* Individuals who decline participation or request withdrawal at any stage of the study",{"count":519,"type":23},2020,"1 Day","This study aims to develop a video and audio database for teaching and learning clinical skills in occupational therapy. The database will include recordings of clinical teaching sessions, skill demonstrations, student practice, and interactions between occupational therapists, trainees, and patients or family members.\n\nParticipants may include occupational therapists involved in clinical teaching, occupational therapy interns or postgraduate trainees, and adult patients or family members who receive occupational therapy services. Participation involves voluntary video or audio recording of clinical teaching or therapy-related activities after informed consent is obtained.\n\nThis study does not involve any experimental treatment, intervention, or comparison of outcomes. The collected materials will be securely stored, anonymized, and organized for future educational use and research on clinical skills teaching and assessment in occupational therapy.",[523,524,525],"Occupational Therapy Education","Occupational Therapy","Clinical Competence",[527,528,529],"Occupational therapy education","Clinical skills training","Clinical competence",{"date":484,"type":36},{"date":532,"type":36},"2026-02-01",{"date":534,"type":23},"2034-12-31",{"name":42,"class":43},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":18,"sex":543,"minAge":544,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":55,"phases":548,"briefSummary":549,"conditions":550,"keywords":554,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":44},"100629300","multi-acupoint-laser-therapy-for-body-shape-and-composition-in-obese-menopausal-women-100629300","NCT07472881","Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women","Effects of a Multi-acupoint Laser Therapy Device on Body Shape and Body Composition in Obese Menopausal Women","Inclusion Criteria:\n\n* Female participants aged 45 to 55 years\n* No cognitive impairment or major psychiatric disorder\n* Able to understand the study procedures and communicate with research staff\n* Body mass index (BMI) \\> 24 kg\u002Fm² OR waist-to-hip ratio \\> 0.88\n\nExclusion Criteria:\n\n* Pregnant or possibly pregnant women\n* Diagnosed chronic diseases currently under active treatment, including hepatitis, chronic kidney disease, chronic gastrointestinal disease, cardiovascular disease, or cancer\n* Systemic diseases such as hyperthyroidism, hypothyroidism, compensated liver cirrhosis, or autoimmune disorders\n* Currently receiving weight control treatment, including bariatric surgery or weight-loss medications\n* History of epilepsy or seizure disorder\n* Coagulation disorders or current use of anticoagulant therapy","FEMALE","45 Years","55 Years",{"count":547,"type":23},40,[57],"The purpose of this study is to integrate Traditional Chinese Medicine (TCM) theory and therapeutic methods with modern low-level laser stimulation on corresponding acupoints, applying this combined approach to the field of weight management in menopausal women. The trial aims to investigate whether lifestyle modifications in accordance with WHO guidelines (dietary control and exercise), combined with adjunctive low-level laser acupuncture, can enhance weight reduction and improve body composition more effectively than standard lifestyle interventions alone.",[551,552,28,553],"Menopause","Perimenopause","Overweight",[555,556,28,551,557,558,559,560],"Laser acupuncture","Low-level laser therapy","Body composition","Weight management","Acupoint stimulation","Randomized controlled trial","2026-03-18",{"date":563,"type":36},"2026-03-20",{"date":565,"type":36},"2026-03-16",{"date":567,"type":23},"2029-01-24",{"name":42,"class":43},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":55,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":44},"100564399","developing-and-testing-the-effect-of-online-interactive-videos-in-improving-low-anterior-resection-syndrome-100564399","NCT06628674","Developing and Testing the Effect of Online Interactive Videos in Improving Low Anterior Resection Syndrome.","Developing and Testing the Effect of Online Interactive Videos in Improving Low Anterior Resection Syndrome, Psychological Distress,and Quality of Life","Inclusion Criteria:\n\n1. Stage I-III rectal cancer.\n2. Patients already know their condition.\n3. Aged 20 years and older.\n4. Consciously communicate in Mandarin or Taiwanese.\n5. Agreed with the interview and had signed the permit.\n\nExclusion Criteria:\n\n1. Recurrent rectal cancer.\n2. Stage IV rectal cancer.",{"count":577,"type":23},110,[57],"This study aims to develop and test the effect of online interactive videos in improving LARS.",[581],"Rectal Cancer",{"date":563,"type":36},{"date":584,"type":36},"2024-11-15",{"date":586,"type":23},"2028-01-31",{"name":42,"class":43},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":19,"minAge":469,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":55,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":44},"100552011","phase-2-novel-augmentation-of-daoib-and-antioxidant-for-early-dementia-100552011","NCT06467539","Novel Augmentation of DAOIB and Antioxidant for Early Dementia","Inclusion Criteria:\n\n* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment\n* MMSE between 10-26\n* CDR 1 or 0.5\n\nExclusion Criteria:\n\n* Hachinski Ischemic Score \\> 4\n* Substance abuse\u002Fdependence\n* Parkinson disease, epilepsy, dementia with psychotic features\n* Major depressive disorder\n* Major physical illnesses\n* Severe visual or hearing impairment","90 Years",{"count":499,"type":23},[219],"Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.",[599,476],"Alzheimer Disease",{"date":601,"type":36},"2026-03-19",{"date":603,"type":36},"2024-06-19",{"date":605,"type":23},"2027-05",{"name":42,"class":43},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":18,"sex":19,"minAge":614,"maxAge":344,"enrollmentInfo":615,"targetDuration":4,"studyType":55,"phases":616,"briefSummary":617,"conditions":618,"keywords":621,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":44},"100538394","phase-1-fecal-microbiota-transplantation-for-patients-with-autism-spectrum-disorder-100538394","NCT06290258","Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.","Fecal Microbiota Transplantation for Gastrointestinal, Autistic, Emotion, and Behavior Symptoms of Patients With Autism Spectrum Disorder and Gastrointestinal Problems: a Preliminary Study.","Inclusion Criteria:\n\n* Diagnosed by a child psychiatrist in line with DSM-5 Autism Spectrum Disorder\n* Combined with gastrointestinal problems, any Gastrointestinal Symptoms Rating Scale score≧3.\n* Age is between 7-30.\n* Participants who are willing to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n* Cases where clinical assessment cannot cooperate with fecal microbiota transplantation and examination.\n* Cases requiring antibiotics within 3 months before or after acceptance because of their physiological condition.\n* Cases requiring long-term use of proton pump inhibitors due to their physiological conditions.\n* Severe physical diseases, such as acute gastrointestinal diseases, severe malnutrition or underweight, immunodeficiency diseases, severe allergies or autoimmune diseases, brain injuries or severe organic brain diseases, will affect the evaluation of treatment results.\n* Severe mental illness, such as schizophrenia, bipolar disorder, etc.\n* Those who used probiotics one month before the case may affect the intestinal flora.\n* Pregnancy.\n* Cases that cannot understand the content of this research.\n* Participants who are unwilling to participate in the study or refuse to sign the informed consent.\n* Participants who are not suitable to include in this study, evaluate by PI or Co-PI.","7 Years",{"count":346,"type":23},[272,219],"This study aims to evaluate the efficacy of fecal microbiota transplantation on the gastrointestinal symptoms, autistic symptoms and emotional behavior symptoms of patients with autism spectrum disorder, and investigate the relations between the brain-gut axis, cytokines and autism spectrum disorder. Fecal microbiota transplantation have the potentials to improve intestinal microbiota composition, regulate immunity, and then improve gastrointestinal symptoms, autistic symptoms, emotional behavior symptoms and sleep of children with autism spectrum disorder. Early intervention at school-age may even benefit development, improve cognition and prognosis.",[350,619,620],"Gastrointestinal Diseases","Healthy",[622,350,623,624,625],"Fecal Microbiota Transplantation","gastrointestinal problems","cytokines","cognitive function",{"date":563,"type":36},{"date":628,"type":36},"2024-03-06",{"date":179,"type":23},{"name":42,"class":43},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":637,"enrollmentInfo":638,"targetDuration":4,"studyType":55,"phases":640,"briefSummary":641,"conditions":642,"keywords":644,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":651,"locationsCount":44},"100535954","effects-of-circuit-training-combining-different-types-of-distal-robot-assisted-and-task-oriented-therapy-on-motor-control-motor-and-daily-functions-and-quality-of-life-after-stroke-100535954","NCT06258538","Effects of Circuit Training Combining Different Types of Distal Robot-assisted and Task-oriented Therapy on Motor Control, Motor and Daily Functions, and Quality of Life After Stroke","Inclusion Criteria:\n\n1. unilateral stroke ≥ 3 months onset\n2. Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score between 18 to 56, indicating different levels of motor impairments ;\n3. without excessive spasticity in any of the UE joint (modified Ashworth scale ≤3 in proximal joints and modified Ashworth scale ≤2 in distal joints);\n4. Mini Mental State Exam (MMSE) score \\> 24, indicating no serious cognitive impairment;\n5. between the ages of 20 and 75 years -\n\nExclusion Criteria:\n\n1. histories of other neurological diseases such as dementia, Parkinson's disease, and peripheral polyneuropathy;\n2. difficulties in following and understanding instructions such as global aphasia;\n3. enroll in other rehabilitation or drug studies simultaneously;\n4. receiving Botulinum toxin injections within 3 months. -","75 Years",{"count":639,"type":23},87,[57],"This study proposes a novel stroke rehabilitation approach for upper extremity training by firstly combining different types of distal robot-assisted and task-oriented therapy in a circuit training program. The program could enhance UE functions, improving daily function, decrease caregiver burden and lower medical expenses associated with long-term care. Professionals can use these findings to promote the application of clinically empirical research and better understand the effects and mechanisms of circuit training.",[643],"Stroke Patients",[645,646],"Stroke rehabilitation","distal upper extremity",{"date":563,"type":36},{"date":649,"type":36},"2024-06-01",{"date":259,"type":23},{"name":42,"class":43},""]